TheraSim (Durham, NC) a commercial-stage medical technology company focused on a suite of clinical performance management tools, closed a $1.2M Series A financing. Participants include Andromeda Capital.

PhaseBio Pharmaceuticals (Research Triangle Park, NC) a development-stage biopharma company focused on elastin-like fusion proteins for improved expression and purification of biological, closed a $25M Series B financing. Participants include New Enterprise Associates, Hatteras Venture Partners, Johnson & Johnson Development Corp. and Fletcher Spaght Ventures.

ABT Molecular Imaging (Knoxville, TN) medical imaging company developing a production platform to generate unit doses of molecular imaging drugs for positron emission tomography (PET) scanning at the point of use, closed a $9M Series A financing. Participants include Intersouth Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

TransEnterix (Durham, NC) a development-stage medical device company focused on a laparoscopic surgical platform for minimally invasive abdominal surgeries, closed a $55M Series B financing. Participants include Aisling Capital, Intersouth Partners, Quaker BioVentures, SV Life Science Advisers, Synergy Life Science Partners and Parish Capital Advisors.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Centice (Morrisville, NC) developer of a pharmaceutical verification device to improve accuracy of dispensed medications, closed a $6.1M Series C financing. Participants include Fulcrum Financial Group, The Aurora Funds, S-Group Direct Investments, Innovation Ventures and Novak Biddle Venture Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

Kerederm (Blacksburg, VA) a development-stage medical device company focused on the use of germicidal phototherapy to prevent and treat skin and nail infections, closed a $2.5M Series A financing. Participants include NewVa Capital Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

Metabolon (Durham, NC) a metabolomics services and informatics company focused on detection of small molecule biomarkers, closed a $6M Series C financing, bringing the entire financing round to $12.3M. Participants include Syngenta Ventures, Fletcher Spaght Ventures, Sevin Rosen Funds, Aurora Funds, Harris and Harris Group, Fulcrum Financial Partners and Alexandria Equities.

Micell Technologies (Raleigh, NC) a development-stage medical device company focused on a fluid-based drug eluting stents for the interventional cardiology market, closed a $15M Series B financing. Participants to date have included St.Jude Medical, Invemed Catalyst Fund and GE.

Almeria Sciences (Atlanta, GA) a clinical-stage biopharma company focused on ophthalmic disease and treatment of diabetic macular edema, closed a $5M Series C, bringing the total round to $35. Participants have included Polaris Venture Partners, Intersouth Partners, Venrock Associates, Domain Associates and Scale Venture Partners.

Union Springs Pharmaceuticals (Union, KY) a commercial-stage developer of OTC antiinfective washes for emergency first responders, closed a $5M Series A financing. Participants include Blue Chip Venture Company.